BiotechTube
Home/Madrigal Pharmaceuticals/David Soergel, M.D.
DS

David Soergel, M.D.

Executive Vice President, Chief Medical Officer

Madrigal Pharmaceuticals

Therapeutic Areas

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic Disease

Madrigal Pharmaceuticals Pipeline

DrugIndicationPhase
Resmetirom (Rezdiffra™)MASH with moderate to advanced fibrosis (F2-F3)Approved
ResmetiromMASH with compensated cirrhosis (F4)Phase 3

Leadership Team at Madrigal Pharmaceuticals

BS
Bill Sibold
Chief Executive Officer and Director
RT
Rebecca Taub, M.D.
Founder and Director
View full Madrigal Pharmaceuticals profile